Avadel XWPharma partnership secures global rights to valiloxybate, targeting narcolepsy and idiopathic hypersomnia.
Browsing: M&A and Licensing
News and insights on mergers, acquisitions, licensing deals, and strategic collaborations across the global pharma industry.
Enlaza Vertex collaboration forms a $2.4 billion deal to advance autoimmune therapies using War-Lock technology.
Servier Fragile X acquisition involves KER-0193, enhancing its neurology pipeline with a $450m deal.
Novartis Tourmaline Bio acquisition for $1.4bn expands its cardiovascular portfolio with pacibekitug.
OMass Genentech collaboration targets inflammatory bowel disease with a $400 million deal, leveraging OdyssION platform.
Avadel licenses sleep drug for $20M upfront, expanding its portfolio with XWPharma’s valiloxybate.
Bravehart Hengrui licensing involves a drug for hypertrophic cardiomyopathy, challenging Bristol Myers’ Camzyos in China.
Novartis licenses RNA medicine from Arrowhead in $200M deal
• Novartis signs billion-dollar biobuck deal with Argo in Shanghai. • Deal focuses on siRNA medicines development. • Novartis continues strategic investments in RNA-based therapies. Novartis signs a billion-dollar biobuck deal with Shanghai-based biotech company Argo, marking one of the largest agreements of its kind this year. The Swiss pharmaceutical giant is investing heavily in the development of small interfering RNA (siRNA) medicines, a promising area in the treatment of various diseases. This agreement follows a similar commitment made just a day earlier, highlighting Novartis’s strategic focus on RNA-based therapies. The financial terms of the deal include billions in potential…
Remedy Meds is buying Thirty Madison, a virtual care startup that competes with the likes of Hims and Ro.
Remedy Meds, which sells GLP-1 weight loss medications and provides telehealth services directly to consumers, will ….